Bioporto A/S
OTC:THOXF

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
OTC:THOXF
Watchlist
Price: 0.288 USD Market Closed
Market Cap: $123.7m

Operating Margin

-255.4%
Current
Declining
by 29.7%
vs 3-y average of -225.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-255.4%
=
Operating Income
kr-93.4m
/
Revenue
kr36.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-255.4%
=
Operating Income
$-93.4m
/
Revenue
kr36.6m

Peer Comparison

Country Company Market Cap Operating
Margin
DK
Bioporto A/S
CSE:BIOPOR
462.9m DKK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 96% of companies in Denmark
Percentile
4rd
Based on 506 companies
4rd percentile
-255.4%
Low
-5 981.6% — 1.3%
Typical Range
1.3% — 16.3%
High
16.3% — 423.3%
Distribution Statistics
Denmark
Min -5 981.6%
30th Percentile 1.3%
Median 7.5%
70th Percentile 16.3%
Max 423.3%

Bioporto A/S
Glance View

Market Cap
123.7m USD
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

THOXF Intrinsic Value
0.295 USD
Undervaluation 2%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-255.4%
=
Operating Income
kr-93.4m
/
Revenue
kr36.6m
What is Bioporto A/S's current Operating Margin?

The current Operating Margin for Bioporto A/S is -255.4%, which is below its 3-year median of -225.7%.

How has Operating Margin changed over time?

Over the last 3 years, Bioporto A/S’s Operating Margin has increased from -282.1% to -255.4%. During this period, it reached a low of -282.1% on Sep 30, 2022 and a high of -171.2% on Jun 30, 2024.

Back to Top